In recent developments within the Chinese pharmaceutical sector, a series of significant out-licensing agreements has emerged, indicating a strategic shift from low-cost production to innovative capabilities. Companies like CSPC Pharmaceutical and RemeGen have secured deals potentially worth billions, with Haisco Pharmaceutical partnering with AbbVie on pain treatment molecules valued at up to $745 million. This trend underlines China’s growing role in the global pharmaceutical value chain and is likely driven by the integration of artificial intelligence in drug development. Analysts foresee a continued expansion of China’s influence in international markets.
Disclaimer: This summary is written by AI, which can make mistakes. Please follow up on any news information from additional sources.
Link to original article source: https://www.indexbox.io/blog/chinese-biotech-firms-secure-major-global-licensing-agreements-in-strategic-shift/
